Plus Therapeutics announced on November 14, 2024, that it obtained agreement from the FDA to initiate a Phase 1 trial. This trial will evaluate multiple doses of Rhenium (186 Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM).
This FDA agreement represents a key next step in the integrated development plan for Rhenium (186 Re) Obisbemeda in LM patients. The company is focused on advancing its CNS cancer therapies.
Management stated that Plus Therapeutics is on track to complete both Phase 1 LM trials and progress to later stage trials in 2025. This indicates a clear development pathway for the lead drug candidate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.